Daré Bioscience soars on birth control device trial data

Shares of women’s health firm Daré Bioscience DARE.O rise 88% to $4.72

Stock set for best day in over 5 years, if gains hold

Co says its medical device, Ovaprene, showed a pregnancy rate of about 9% among participants, in an ongoing late-stage study, in line with previous results

Ovaprene is an investigational, hormone-free, monthly intravaginal device to prevent pregnancy

An independent safety board reviewed the data and recommended the study continue without changes, co says

Vaginal odor was the main side effect, leading 17% of participants to leave the study

Ovaprene works by releasing a non-hormonal agent that slows sperm and uses a polymer barrier to block them from reaching the cervix

Including session moves, stock up 50% YTD